Preclinical research across multiple cancer types now shows that the NAD+ salvage pathway, the same biological mechanism targeted by popular anti-aging supplements like nicotinamide mononucleotide ...

GAITHERSBURG, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a privately-held clinical-stage pharmaceutical company transforming the field of NAMPT inhibition, announced today the ...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics (Remedy Plan), a privately-held, clinical-stage pharmaceutical company developing novel, hyperbolic NAMPT inhibitors, today ...

Polymorphisms in the NAMPT gene, which encodes the adipocytokine visfatin/nicotinamide phosphorybosil transferase (NAMPT), affect the circulating visfatin/NAMPT levels and are associated with obesity ...

In this new article publication from Acta Pharmaceutica Sinica B, authors Ying Wu, Congying Pu, Yixian Fu, Guoqiang Dong, Min Huang and Chunquan Sheng from Second Military Medical University, Shanghai ...

In this new article publication from Acta Pharmaceutica Sinica B, authors Ying Wu, Congying Pu, Yixian Fu, Guoqiang Dong, Min Huang and Chunquan Sheng from Second Military Medical University, Shanghai ...

A new collaboration has been announced to advance research and drug development for neurodegenerative disorders caused by the aging and death of nerve cells. Death of nerve cells is the key mechanism ...

Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203 The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug ...

INTRODUCTION Visceral adipose tissue is the main source of circulating proinflammatory adipokine, visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT), whose role in the pathogenesis of ...

Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase ...